An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients’ Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes
Gérard Reach,1 Laurent Benarbia,2 Pierre-Yves Benhamou,3 Brigitte Delemer,4 Séverine Dubois,5 Didier Gouet,6 Bruno Guerci,7 Nathalie Jeandidier,8 Karim Lachgar,9 Gilles Le Pape,10 Rémy Leroy,11 Jean-Hugues Masgnaux,12 Philippe Raclet,13 Yves Reznik,14 Jean-Pierre Riveline,15,16 Pauline Schaepelynck,...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-05-01
|
| Series: | Patient Preference and Adherence |
| Subjects: | |
| Online Access: | https://www.dovepress.com/an-unsafesafe-typology-in-people-with-type-2-diabetes-bridging-patient-peer-reviewed-fulltext-article-PPA |
| _version_ | 1818238446748041216 |
|---|---|
| author | Reach G Benarbia L Benhamou PY Delemer B Dubois S Gouet D Guerci B Jeandidier N Lachgar K Le Pape G Leroy R Masgnaux JH Raclet P Reznik Y Riveline JP Schaepelynck P Vambergue A Vergès B |
| author_facet | Reach G Benarbia L Benhamou PY Delemer B Dubois S Gouet D Guerci B Jeandidier N Lachgar K Le Pape G Leroy R Masgnaux JH Raclet P Reznik Y Riveline JP Schaepelynck P Vambergue A Vergès B |
| author_sort | Reach G |
| collection | DOAJ |
| description | Gérard Reach,1 Laurent Benarbia,2 Pierre-Yves Benhamou,3 Brigitte Delemer,4 Séverine Dubois,5 Didier Gouet,6 Bruno Guerci,7 Nathalie Jeandidier,8 Karim Lachgar,9 Gilles Le Pape,10 Rémy Leroy,11 Jean-Hugues Masgnaux,12 Philippe Raclet,13 Yves Reznik,14 Jean-Pierre Riveline,15,16 Pauline Schaepelynck,17 Anne Vambergue,18 Bruno Vergès19 1Health Education and Promotion Laboratory (LEPS EA 3412), Sorbonne Paris Nord University, Bobigny, France; 2Marketing Studio, Paris, France; 3Department of Endocrinology, Grenoble University Hospital; Grenoble Alpes University, INSERM U1055, LBFA, Grenoble, France; 4Service d’Endocrinologie – Diabète – Nutrition, CHU de Reims - Hôpital Robert Debré, and Université de Reims Champagne Ardenne, UFR Sciences Exactes Et Naturelles, Reims, France; 5Department of Diabetology and Endocrinology, CHU Angers, Angers, France; 6Department of Diabetology and Endocrinology, Saint Louis Hospital, La Rochelle, France; 7Department of Endocrinology, Diabetology and Nutrition, CHRU of Nancy, Brabois Hospital, and ILCV Lorraine University, Vandoeuvre-les-Nancy, France; 8Department of Endocrinology, Diabetes and Nutrition, Hôpitaux Universitaires de Strasbourg, and Université de Strasbourg, Strasbourg, France; 9Department of Diabetology and Endocrinology, Centre Hospitalier Simone Veil, Eaubonne, France; 10General Practice, Penmarc’h, France; 11Private Medical Practice, Endocrinology and Diabetology, Lille, France; 12M&M Conseil, Boulogne, France; 13Association Française des Diabétiques de Bourgogne Franche-Comté, Dijon, France; 14Department oEndocrinology and Diabetology, CHU Côte de Nacre, Caen, and University of Caen Basse-Normandie, Medical School, Caen, France; 15Department of Diabetology and Endocrinology, Lariboisière Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France; 16Unité INSERM U1138 Immunity and Metabolism in Diabetes, ImMeDiab Team, Centre de Recherches des Cordeliers, and Université de Paris, Paris, France; 17Department of Nutrition-Endocrinology-Metabolic Diseases, Pôle ENDO, APHM-Hôpital la Conception, Marseille, France; 18Department of Diabetology, Endocrinology, Metabolism and Nutrition, CHU Lille, and University Hospital European Genomic Institute for Diabetes, Lille, France; 19Department of Endocrinology-Diabetology,CHU Dijon, and University of Burgundy, INSERM LNC UMR1231, Dijon, FranceCorrespondence: Gérard Reach, Health Education and Promotion Laboratory (LEPS EA 3412), Sorbonne Paris Nord University, 74 Rue Marcel Cachin, Bobigny Cedex, 93017, France, Tel + 33 (0)6 60 84 53 25, Email gerardreach@icloud.comBackground: Support programs are provided to people with diabetes to help them manage their disease. However, adherence to and persistence in support programs are often low, making it difficult to demonstrate their effectiveness.Aim: To identify the determinants of patients’ perceived interest in diabetes support programs because it may be a powerful determinant of effective participation in such programs.Patients and Methods: An online study conducted in April 2021 in metropolitan France on 600 people with diabetes recruited from a consumer panel. A 64-item psychosocial questionnaire including a question asking to evaluate the helpfulness of a support program was used. Univariate, multivariate, and multiple correspondence analyses were performed.Results: The existence of a typology, known as Unsafe/Safe, was discovered, in which patients with type 2 diabetes respond in two distinct ways. Type U (unsafe) patients, who believe that a support program would be helpful, are more likely to be nonadherent to their treatment, have high hemoglobin A1c levels, have at least one diabetic complication, lack information regarding their disease and treatment, rate the burden of their disease and impairment of their quality of life as high, worry about their future, and are pessimistic. Type S (safe) patients have the opposite characteristics. Type U patients can be dichotomized into two broad classes: one in which they lack information regarding disease and treatment and the other in which alterations in the quality of life and burden of the disease predominate. Insulin-treated patients give more importance to the lack of information, whereas noninsulin-treated patients complain primarily about the burden of the disease and impairment of quality of life.Conclusion: This study describes this new U/S typology, proposes a simple method based on a nine-item questionnaire to identify type U patients by calculating a Program Helpfulness Score described herein, and clarifies the nature of the intervention to be provided to them. This novel approach could be applied to other chronic diseases.Keywords: type 2 diabetes, adherence, support programs, typology, personality traits, clinical outcomes, patients’ expectations |
| first_indexed | 2024-12-12T12:41:47Z |
| format | Article |
| id | doaj.art-95f679704f194453a42364c7a9d89a16 |
| institution | Directory Open Access Journal |
| issn | 1177-889X |
| language | English |
| last_indexed | 2024-12-12T12:41:47Z |
| publishDate | 2022-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj.art-95f679704f194453a42364c7a9d89a162022-12-22T00:24:12ZengDove Medical PressPatient Preference and Adherence1177-889X2022-05-01Volume 161333135075510An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients’ Expectations, Personality Traits, Medication Adherence, and Clinical OutcomesReach GBenarbia LBenhamou PYDelemer BDubois SGouet DGuerci BJeandidier NLachgar KLe Pape GLeroy RMasgnaux JHRaclet PReznik YRiveline JPSchaepelynck PVambergue AVergès BGérard Reach,1 Laurent Benarbia,2 Pierre-Yves Benhamou,3 Brigitte Delemer,4 Séverine Dubois,5 Didier Gouet,6 Bruno Guerci,7 Nathalie Jeandidier,8 Karim Lachgar,9 Gilles Le Pape,10 Rémy Leroy,11 Jean-Hugues Masgnaux,12 Philippe Raclet,13 Yves Reznik,14 Jean-Pierre Riveline,15,16 Pauline Schaepelynck,17 Anne Vambergue,18 Bruno Vergès19 1Health Education and Promotion Laboratory (LEPS EA 3412), Sorbonne Paris Nord University, Bobigny, France; 2Marketing Studio, Paris, France; 3Department of Endocrinology, Grenoble University Hospital; Grenoble Alpes University, INSERM U1055, LBFA, Grenoble, France; 4Service d’Endocrinologie – Diabète – Nutrition, CHU de Reims - Hôpital Robert Debré, and Université de Reims Champagne Ardenne, UFR Sciences Exactes Et Naturelles, Reims, France; 5Department of Diabetology and Endocrinology, CHU Angers, Angers, France; 6Department of Diabetology and Endocrinology, Saint Louis Hospital, La Rochelle, France; 7Department of Endocrinology, Diabetology and Nutrition, CHRU of Nancy, Brabois Hospital, and ILCV Lorraine University, Vandoeuvre-les-Nancy, France; 8Department of Endocrinology, Diabetes and Nutrition, Hôpitaux Universitaires de Strasbourg, and Université de Strasbourg, Strasbourg, France; 9Department of Diabetology and Endocrinology, Centre Hospitalier Simone Veil, Eaubonne, France; 10General Practice, Penmarc’h, France; 11Private Medical Practice, Endocrinology and Diabetology, Lille, France; 12M&M Conseil, Boulogne, France; 13Association Française des Diabétiques de Bourgogne Franche-Comté, Dijon, France; 14Department oEndocrinology and Diabetology, CHU Côte de Nacre, Caen, and University of Caen Basse-Normandie, Medical School, Caen, France; 15Department of Diabetology and Endocrinology, Lariboisière Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France; 16Unité INSERM U1138 Immunity and Metabolism in Diabetes, ImMeDiab Team, Centre de Recherches des Cordeliers, and Université de Paris, Paris, France; 17Department of Nutrition-Endocrinology-Metabolic Diseases, Pôle ENDO, APHM-Hôpital la Conception, Marseille, France; 18Department of Diabetology, Endocrinology, Metabolism and Nutrition, CHU Lille, and University Hospital European Genomic Institute for Diabetes, Lille, France; 19Department of Endocrinology-Diabetology,CHU Dijon, and University of Burgundy, INSERM LNC UMR1231, Dijon, FranceCorrespondence: Gérard Reach, Health Education and Promotion Laboratory (LEPS EA 3412), Sorbonne Paris Nord University, 74 Rue Marcel Cachin, Bobigny Cedex, 93017, France, Tel + 33 (0)6 60 84 53 25, Email gerardreach@icloud.comBackground: Support programs are provided to people with diabetes to help them manage their disease. However, adherence to and persistence in support programs are often low, making it difficult to demonstrate their effectiveness.Aim: To identify the determinants of patients’ perceived interest in diabetes support programs because it may be a powerful determinant of effective participation in such programs.Patients and Methods: An online study conducted in April 2021 in metropolitan France on 600 people with diabetes recruited from a consumer panel. A 64-item psychosocial questionnaire including a question asking to evaluate the helpfulness of a support program was used. Univariate, multivariate, and multiple correspondence analyses were performed.Results: The existence of a typology, known as Unsafe/Safe, was discovered, in which patients with type 2 diabetes respond in two distinct ways. Type U (unsafe) patients, who believe that a support program would be helpful, are more likely to be nonadherent to their treatment, have high hemoglobin A1c levels, have at least one diabetic complication, lack information regarding their disease and treatment, rate the burden of their disease and impairment of their quality of life as high, worry about their future, and are pessimistic. Type S (safe) patients have the opposite characteristics. Type U patients can be dichotomized into two broad classes: one in which they lack information regarding disease and treatment and the other in which alterations in the quality of life and burden of the disease predominate. Insulin-treated patients give more importance to the lack of information, whereas noninsulin-treated patients complain primarily about the burden of the disease and impairment of quality of life.Conclusion: This study describes this new U/S typology, proposes a simple method based on a nine-item questionnaire to identify type U patients by calculating a Program Helpfulness Score described herein, and clarifies the nature of the intervention to be provided to them. This novel approach could be applied to other chronic diseases.Keywords: type 2 diabetes, adherence, support programs, typology, personality traits, clinical outcomes, patients’ expectationshttps://www.dovepress.com/an-unsafesafe-typology-in-people-with-type-2-diabetes-bridging-patient-peer-reviewed-fulltext-article-PPAtype 2 diabetesadherencesupport programstypologypersonality traitsclinical outcomespatients’ expectations |
| spellingShingle | Reach G Benarbia L Benhamou PY Delemer B Dubois S Gouet D Guerci B Jeandidier N Lachgar K Le Pape G Leroy R Masgnaux JH Raclet P Reznik Y Riveline JP Schaepelynck P Vambergue A Vergès B An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients’ Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes Patient Preference and Adherence type 2 diabetes adherence support programs typology personality traits clinical outcomes patients’ expectations |
| title | An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients’ Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes |
| title_full | An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients’ Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes |
| title_fullStr | An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients’ Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes |
| title_full_unstemmed | An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients’ Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes |
| title_short | An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients’ Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes |
| title_sort | unsafe safe typology in people with type 2 diabetes bridging patients rsquo expectations personality traits medication adherence and clinical outcomes |
| topic | type 2 diabetes adherence support programs typology personality traits clinical outcomes patients’ expectations |
| url | https://www.dovepress.com/an-unsafesafe-typology-in-people-with-type-2-diabetes-bridging-patient-peer-reviewed-fulltext-article-PPA |
| work_keys_str_mv | AT reachg anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT benarbial anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT benhamoupy anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT delemerb anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT duboiss anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT gouetd anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT guercib anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT jeandidiern anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT lachgark anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT lepapeg anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT leroyr anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT masgnauxjh anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT racletp anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT rezniky anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT rivelinejp anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT schaepelynckp anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT vamberguea anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT vergesb anunsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT reachg unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT benarbial unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT benhamoupy unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT delemerb unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT duboiss unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT gouetd unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT guercib unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT jeandidiern unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT lachgark unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT lepapeg unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT leroyr unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT masgnauxjh unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT racletp unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT rezniky unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT rivelinejp unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT schaepelynckp unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT vamberguea unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes AT vergesb unsafesafetypologyinpeoplewithtype2diabetesbridgingpatientsrsquoexpectationspersonalitytraitsmedicationadherenceandclinicaloutcomes |